Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects (D5890L00013)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00691951|
Recruitment Status : Completed
First Posted : June 6, 2008
Last Update Posted : October 21, 2008
A reduced response to inhaled corticosteroids (ICS) has been reported in smoking compared to non-smoking asthmatic patients. However, the comparative response to other currently prescribed medications such as combination therapy of long-acting beta agonists and ICS remain to be further evaluated.
No significant differences were found between our group of subjects in regard to changes in asthma control pulmonary function and airway inflammation following budesonide or the association of budesonide with formoterol for a period of 2 months. This should be further explored in larger groups of subjects.
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: budesonide and budesonide/formoterol||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Comparative Effects of Budesonide and Budesonide/Formoterol (Symbicort) on Asthma Control in Smoking Asthmatic Subjects: A Pilot Study|
- Comparative changes before and after treatments in each group for Asthma Control Questionnaire (ACQ)
- Other control scores (ACSS score) and rescue B2 agonist need
- Comparative changes in FEV1
- Quality of life questionnaire
- Morning and evening PEF
- Total and differential cell counts in induced sputum and ECP and MPO
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00691951
|Hôpital du Sacré-Coeur de Montreal|
|Montréal, Quebec, Canada, H4J 1C5|
|Quebec, Canada, G1V 4G5|